DBV Technologies (NASDAQ:DBVT) Shares Gap Up - What's Next?

Key Points

• DBV Technologies shares opened higher at $12.20 versus a prior close of $11.76, though they last traded near $11.99 on relatively light volume.
• Analyst sentiment is broadly positive, with five Buy ratings, one Hold and one Sell. The stock has a consensus “Moderate Buy” rating and an average price target of $48.50, including a $55 target from Citizens JMP.
• Institutional ownership is substantial at 71.74%, with several hedge funds establishing or expanding positions. DBV is developing Viaskin, including an investigational peanut-allergy patch for children.

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $11.76, but opened at $12.20. DBV Technologies shares last traded at $11.99, with a volume of 29,690 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on DBVT shares. Citizens Jmp lifted their target price on DBV Technologies from $47.00 to $55.00 and gave the stock a "market outperform" rating in a research note on Tuesday, June 30th. Wall Street Zen downgraded DBV Technologies from a "hold" rating to a "sell" rating in a research report on Saturday, July 4th. Cantor Fitzgerald reissued an "overweight" rating on shares of DBV Technologies in a report on Thursday, September 10th. Weiss Ratings lowered DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, July 17th. Finally, HC Wainwright reiterated a "buy" rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, DBV Technologies presently has a consensus rating of "Moderate Buy" and an average price target of $48.50.

DBV Technologies Stock Up 1.9%

The firm has a market capitalization of $753.68 million, a PE ratio of -3.43 and a beta of -0.95. The firm's 50-day simple moving average is $14.11 and its 200-day simple moving average is $17.41.

Hedge Funds Weigh In On DBV Technologies

A number of hedge funds have recently modified their holdings of the company. ADAR1 Capital Management LLC bought a new position in DBV Technologies during the 1st quarter valued at approximately $21,159,000. Perceptive Advisors LLC purchased a new stake in shares of DBV Technologies in the 1st quarter worth about $20,146,000. Elmind Capital LP purchased a new stake in DBV Technologies in the first quarter worth about $5,536,000. UBS Group AG grew its stake in shares of DBV Technologies by 165,347.3% in the 4th quarter. UBS Group AG now owns 244,862 shares of the company's stock worth $4,694,000 after buying an additional 244,714 shares during the last quarter. Finally, Vivo Capital LLC grew its stake in shares of DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock worth $55,726,000 after acquiring an additional 205,943 shares during the last quarter. Hedge funds and other institutional investors own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies' primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.